share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4:持股变动声明-董事 Dar Zavain
美股SEC公告 ·  07/03 16:41
Moomoo AI 已提取核心信息
Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on July 1, 2024. The transaction involved a grant of 1,843 shares of Class A Common Stock at no cost. Following the transaction, Zavain's direct holdings in the company increased to a total of 103,996 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing commitment to align the interests of its employees with those of shareholders.
Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on July 1, 2024. The transaction involved a grant of 1,843 shares of Class A Common Stock at no cost. Following the transaction, Zavain's direct holdings in the company increased to a total of 103,996 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing commitment to align the interests of its employees with those of shareholders.
Dar Zavain与Recursion Pharmaceuticals,Inc. [RXRX]有关,于2024年7月1日完成了股票收购交易。该交易涉及授予1,843股A类普通股,无需支付任何费用。交易后,Zavain在公司的直接持股总数增至103,996股。该授予是公司股权激励计划的一部分,反映了公司与股东的利益保持一致的不懈努力。
Dar Zavain与Recursion Pharmaceuticals,Inc. [RXRX]有关,于2024年7月1日完成了股票收购交易。该交易涉及授予1,843股A类普通股,无需支付任何费用。交易后,Zavain在公司的直接持股总数增至103,996股。该授予是公司股权激励计划的一部分,反映了公司与股东的利益保持一致的不懈努力。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息